Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Not yet recruitingNCT07795268
Norroy Bioscience Co., LTDProstate Cancer
Start: 2026-08-31End: 2029-08-31Target: 600Updated: 2026-08-31